NEW YORK and BASEL, Switzerland, March 10, 2023 /PRNewswire/ — Sumitovant Biopharma Ltd. (“Sumitovant”) and Myovant Sciences Ltd. (“Myovant”) announced today that Sumitovant has successfully completed its acquisition of Myovant originally announced October 23, 2022. Sumitovant has acquired all outstanding shares of Myovant not already owned by Sumitovant in an all-cash deal with a total […]
News and Media
Publications and resources for members of the press.
Category: Sumitovant
Sumitovant Biopharma Helps Identify More Than 80 Peptide Drug Candidates for Neochromosome’s Differentiated Manufacturing Technology
NEW YORK – January 19, 2023 – Sumitovant Biopharma, Inc. (“Sumitovant”), a technology-driven biopharmaceutical company accelerating the development and commercialization of novel therapeutics, announced it has identified more than 80 peptide drug candidates for manufacturing, using the company’s DrugOME™ computational platform. As part of a collaboration with Neochromosome, Inc. (“Neochromosome”), Sumitovant used extensive natural language […]
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women’s Health and Prostate Cancer Agreement Unanimously Recommended by Special Committee of Myovant’s Independent Directors and Approved by Board NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 /PRNewswire/ — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction with […]
Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
NEW YORK and TOKYO October 2, 2022 — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction with parent company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”), announced today it has submitted a non-binding proposal (the “Proposal”) to the Audit Committee of the Board of Directors (the “Audit Committee”) of Myovant Sciences Ltd. (“Myovant”) offering to acquire all outstanding […]
Sumitovant Biopharma and its Portfolio of Companies Announce Milestone Highlights from the Third Quarter of FY2021
Sumitomo Dainippon Pharma and Sumitovant announced the launch of a phase 1 study of a new drug candidate for carbapenem-resistant bacterial infections. Two publications on Urovant’s FDA-approved OAB therapy, GEMTESA® (vibegron), showed clinical effectiveness and safety in patients with overactive bladder (OAB). Spirovant presented data on an investigational novel recombinant adeno-associated virus gene therapy at […]
Sumitovant and Enzyvant Appoint Bill Symonds, CEO of Altavant Sciences, as Interim Chief Executive Officer of Enzyvant
CAMBRIDGE, Mass. & BASEL, Switzerland, March 2, 2022 – Sumitovant Biopharma and wholly-owned subsidiary Enzyvant, a biopharmaceutical company focused on developing transformative regenerative therapies for patients with rare diseases, today announced the appointment of Bill Symonds, Pharm.D., as interim chief executive officer, effective March 11, 2022. Dr. Symonds has served as the chief executive officer of […]
Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem-Resistant Bacterial Infections
Compound inhibits enzymes produced by bacteria that degrade carbapenem antibiotics LONDON and NEW YORK, February 10, 2022 — Sumitovant Biopharma Ltd., in partnership with its parent company Sumitomo Dainippon Pharma Co., Ltd., recently announced the launch of a phase 1 study in the U.S. on a new drug candidate (“KSP-1007”) for carbapenem-resistant bacterial infections. The […]
Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021
Enzyvant, a wholly-owned subsidiary of Sumitovant, received FDA approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for pediatric congenital athymia Myovant, a publicly listed company that is majority-owned by Sumitovant, and its partner Pfizer received FDA acceptance of its supplemental New Drug Application (sNDA) for MYFEMBREE® Urovant, a wholly-owned subsidiary of Sumitovant, […]
Sumitovant Biopharma Highlights Strong First Fiscal Quarter of 2021 with Significant Commercial and Clinical Achievements Across its Portfolio of Companies
Urovant,a wholly-owned subsidiary of Sumitovant, announced commercial availability of GEMTESA® (vibegron) to treat overactive bladder Myovant, a publicly-listed company that is majority-owned by Sumitovant, and its partner, Pfizer, announced the Food and Drug Administration (FDA) approval of MYFEMBREE® (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for women with uterine fibroids in premenopausal women […]
Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical Development and Corporate Achievements Across its Portfolio of Companies
Urovant became a wholly owned subsidiary of Sumitovant and announced the continuation of its Phase 2a study with novel gene therapy, URO-902 in OAB and urinary incontinence Myovant, a publicly listed company that is majority owned by Sumitovant, made key executive appointments and announced product and pipeline accomplishments including the commercial availability of its first […]